Top

Cancer Immunology, Immunotherapy

Published in:

01-02-2008 | Original Article

Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells

Published in: Cancer Immunology, Immunotherapy | Issue 2/2008

Title: Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells
Publication date: 01-02-2008
Published in: Cancer Immunology, Immunotherapy / Issue 2/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0360-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2008

MAGE-A3161–175 contains an HLA-DRβ4 restricted natural epitope poorly formed through indirect presentation by dendritic cells

PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting

Control of lymphocyte infiltration of lung tumors in mice by host’s genes: mapping of four Lynf (lymphocyte infiltration) loci

Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma

Tumor stromal barriers to the success of adoptive T cell therapy

Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer